Navigation Links
Interim Analysis Supports Continuation of Cell Genesys' VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
Date:1/14/2008

AX immunotherapy for prostate cancer in its bioreactor manufacturing plant in Hayward, California, a facility that is also capable of manufacturing the product during commercialization.

Conference Call and Webcast

Members of the Cell Genesys management team will host a conference call today, Monday, January 14 at 10:00 a.m. ET to discuss today's announcement. Investors may listen to the webcast of the conference call live on the investor section of the Cell Genesys website, http://www.cellgenesys.com. Alternatively, investors may listen to a replay of the call by dialing 800-475-6701 from locations in the United States and 320-365-3844 from outside the United States. The call-in replay and webcast will be available for at least 72 hours following the call. Please refer to reservation number 907247.

About Cell Genesys

Cell Genesys is focused on the development and commercialization of novel biological therapies for patients with cancer. The company is currently pursuing two clinical stage product platforms -- GVAX(TM) cancer immunotherapies and oncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of GVAX immunotherapy for prostate cancer, Phase 2 trials of GVAX immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial of CG0070 oncolytic virus therapy for bladder cancer. Cell Genesys continues to hold an equity interest in its former subsidiary, Ceregene, Inc., which is developing gene therapies for neurodegenerative disorders. Cell Genesys is headquartered in South San Francisco, CA and has its principal manufacturing operation in Hayward, CA. For additional information, please visit the company's website at http://www.cellgenesys.com.

Statements made herein about the company, other than statements of historical fact, including statements about the company's progress, results, analysis
'/>"/>

SOURCE Cell Genesys, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
3. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
4. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
5. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
6. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
7. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
8. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
9. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
10. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
11. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... YORK , September 22, 2014 ... Market Report on "Global Market Study on Ophthalmic Devices: ... by 2020," the global ophthalmic devices market was valued at USD ... at a CAGR of 6.5% from 2014 to 2020, ... in 2020. Browse the full Global Market Study ...
(Date:9/22/2014)... VICTORIA, BC , Sept. 22, 2014 /CNW/ - ... pharmaceutical company focused on developing premium quality medical marijuana ... subsidiary, Thunderbird Biomedical Inc. ("Thunderbird"), has signed a definitive ... Victoria , BC.  The facility has 28,966 ... add approximately 14,500 square feet of mezzanine space for ...
(Date:9/22/2014)... MEETING, Pa. , Sept. 22, 2014 /PRNewswire/ ... announced today it has initiated a phase I ... trial will evaluate the safety, tolerability, and immunogenicity ... 6 (HPV-6), which causes most aerodigestive cancers. ... nose, throat, vocal cords, and parts of the ...
Breaking Medicine Technology:Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 2Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 3Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 4Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 5T-Bird Pharma Inc. to Increase Growing Capacity with Expansion into a 43,500 square feet Second Facility 2T-Bird Pharma Inc. to Increase Growing Capacity with Expansion into a 43,500 square feet Second Facility 3Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 2Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 3Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 4
... Dec. 7, 2010 Royal Philips Electronics (NYSE: PHG, ... of an international analysis on issues and challenges facing ... a greater reliance on home healthcare is necessary to ... growing aging population living longer with chronic illnesses. ...
... /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. ("China-Biotics" or "the Company"), ... manufacturer and distributor of probiotics products in China, ... research and development department presented at the National ... seminar in Hangzhou, China on November 21st. ...
Cached Medicine Technology:Philips-Commissioned RAND Report Highlights Promise of Home Health and Need for Multi-Stakeholder Action to Break Down Barriers to Adoption 2Philips-Commissioned RAND Report Highlights Promise of Home Health and Need for Multi-Stakeholder Action to Break Down Barriers to Adoption 3China-Biotics Attended National Probiotics Seminar 2China-Biotics Attended National Probiotics Seminar 3
(Date:9/22/2014)... whole eye transplant seems futuristic, if not impossible. ... Department of Defense, researchers at University of California, ... make implantation of an entire, functional eye a ... a holy grail for vision restoration," said Jeffrey ... co-recipient with colleagues at University of Pittsburg Medical ...
(Date:9/22/2014)... living in Canada have a higher rate of heart ... while people, McMaster researchers have found. , The ... Association Journal (CMAJ Open) and may be found ... ethnic groups in the country is the more than ... about three percent of the population. They include people ...
(Date:9/22/2014)... -- Recent two-generation approaches to reducing poverty that ... attention from researchers, advocates, and foundations. By combining ... to move to jobs that offer a path ... education for children, these programs aim to improve ... to a new report from the National Center ...
(Date:9/22/2014)... 22, 2014 The R&D of cancer ... years. The statistically important data received from clinical research ... vaccines. The primary challenge to the development of such ... exact mechanism of how a human’s immune system works. ... in different individuals owing to known factors with genetics ...
(Date:9/22/2014)... MONDAY, Sept. 22, 2014 (HealthDay News) -- Scans ... they learn to read. This finding could potentially ... other reading difficulties early on, preliminary research suggests. ... in children with dyslexia as well as most ... Hoeft, an associate professor of child and adolescent ...
Breaking Medicine News(10 mins):Health News:Looking ahead: Whole eye transplant under development 2Health News:Higher risk of heart disease for South Asians in Canada 2Health News:A two-generation lens: Current state policies fail to support families with young children 2Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 2Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 3Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 4Health News:Can Brain Scans Help Predict Young Children's Reading Abilities? 2
... Researchers and staff from Karolinska Institutet are contributing ... of everything from neuroscience to bioentrepreneurship. Carl Johan ... Institutet, is the founder and initiator of ESOF. ... decision-makers, researchers, journalists and the general public meet ...
... ... dedicated to ending malaria deaths and empowering communities, ONE bracelet at a time (Buy a ... Malaria, and encourages others to join in the fight against this deadly disease. Malaria is ... kills a child every 30 seconds. , ...
... suggests that shorter length of leukocyte telomeres chromosome markers ... of cancer and death from cancer, according to a study ... leukocyte is a type of blood cell. Telomeres are ... the replication and stability of the chromosome. Genetic factors and ...
... COLUMBUS, Ohio Scientists have designed a nanoparticle that appears ... effects. In lab experiments, the researchers have found that ... enough into a cell to allow genetic material to be ... is between 2 and 10 times more effective than ...
... linked rejection by a romantic partner to brain activity associated ... published in the July issue of the Journal of ... R. Korey Department of Neurology and of neuroscience at Albert ... author of the study. This is the third publication in ...
... ... of additional foot problems such as bunions, hammertoes, arthritis and calluses, and improve a ... Ankle Surgery. , ... Chicago, IL (Vocus) July 6, 2010 -- Treatment and prevention of adult flatfoot can ...
Cached Medicine News:Health News:News from Karolinska Institutet at ESOF 2010 2Health News:MALAIKA FOR LIFE Takes a Stand in Light of Cheryl Cole's Malaria Bout 2Health News:MALAIKA FOR LIFE Takes a Stand in Light of Cheryl Cole's Malaria Bout 3Health News:Length of biological marker associated with risk of cancer 2Health News:Scientists design new delivery device for gene therapy 2Health News:Scientists design new delivery device for gene therapy 3Health News:Scientists design new delivery device for gene therapy 4Health News:Study links romantic rejection with reward and addiction centers in the brain 2Health News:Don't Ignore Flat Feet,Study links this condition to painful foot maladies 2
The Surgiflex WAVE XP couples the state-of-the-art Surgiflex WAVE Probe with the convenience of a truly portable battery-powered pump....
The original battery-operated suction and irrigation system features a new ergonomic hand piece and superior performance characteristics that have increased the overall flow rate....
... The first step to treatment is ... is an innovative and quick, patient-friendly tool ... female urinary incontinence while minimizing patient discomfort. ... device features a new type of urethral ...
...
Medicine Products: